| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Psycheceutical Bioscience (OTC:BWVI), a company focused on developing innovative technologies for the next generation of mental health treatments, recently hosted Rick Doblin, founder and president of the Multidisciplinary Association for Psychedelic Studies (MAPS), at one of its drug development labs. Doblin, a leading advocate for psychedelic medicine, engaged with Psycheceutical's team to discuss the company's ongoing efforts surrounding its novel NeuroDirect ketamine topical cream for the treatment of PTSD.
During his visit, Doblin met with Psycheceutical's chief visionary officer Zappy Zapolin and CEO Chad Harman to learn about the patented NeuroDirect delivery system. Preclinical study results indicate that this system has the potential to deliver psychedelic medicines safely and effectively, without hallucinogenic effects and with reduced side effects and toxicities.
Doblin commented on the uniqueness of the NeuroDirect topical cream, saying, “I’ve been working in psychedelics for more than 40 years, and it’s rare for me to come across something unique like the NeuroDirect topical cream that is currently being developed by Psycheceutical with the goal of delivering a psychedelic compound without a psychedelic experience or negative side effects.”
Psycheceutical plans to initiate clinical trials for their NeuroDirect ketamine topical cream in Q2. Preliminary results from a pre-clinical study show that the cream could potentially be more cost-effective and provide better patient outcomes than current systemic ketamine treatments for PTSD symptoms. Additionally, 80% of the 100 patients involved in the study reported significant relief from PTSD symptoms within minutes of application, without experiencing psychoactive effects.
Doblin also discussed the possibility of the NeuroDirect topical cream being used as an adjunct treatment for PTSD, noting that it could be helpful during integration therapy following MAPS' macrodoses of MDMA. Furthermore, he expressed interest in the potential application of Psycheceutical’s topical cream delivery system for use with MDMA or other compounds in the future.
As Psycheceutical moves into clinical phase testing and development, Doblin looks forward to reviewing more research data, stating, “Sometimes the biggest breakthroughs are right under our noses.”
Posted In: BWVI
